AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02375217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glycopyrrolate
Study NCT00529048 — intervention group
Intervention type: OTHER
Intervention: Gastric emptying rate
Description: Paracetamol absorption test. Intake of 1,5g of paracetamol followed by measuring the absorption curve
Study NCT01537133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone
Description: Dry Powder Inhaler: 250 mcg/puff, one puff, twice a day
Study NCT00833690 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 mg of inactive substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing adjusted algorithmically to parallel that in the inosine arms
Study NCT01537133 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dry Powder Inhaler: Placebo
Study NCT03640455 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A tDCS (Low Current Transcranial Stimulation) device with two electrodes: active and reference, will be used. The tDCS will be applied next to the cortical representation zone of the primary motor cortex and left pre-motor for 30 minutes; placebo (dummy stimulation), according to the patient's randomization arm.
Study NCT05500768 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hypothermic compression bandage
Description: a compressive bandage is applied for 8 hours to the surgical wound of the cardiac device implants, a frozen prosthesis is added
Study NCT05500768 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional compression bandage
Description: a compressive bandage is applied for 8 hours to the surgical wound of the cardiac device implants
Study NCT03258879 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified CSE
Description: MCSE group: 1 ml of 0.25% bupivacaine will be injected intrathecally
Study NCT03258879 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dural puncture epidural
Description: DPE group: Dural puncture performed, but no medication will be injected intrathecally.
Study NCT00746291 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6 min walk test, Step climbing
Description: walking for 6 minute and climbing steps
Study NCT01353248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS-5885
Description: tablet, 30 mg QD
Study NCT01353248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegobuvir
Description: capsule, 30 mg BID
Study NCT01353248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS-9451
Description: tablet, 200 mg QD
Study NCT01353248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin tablet
Description: (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
Study NCT01353248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS-5885
Description: tablet, 90 mg QD
Study NCT00258427 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation
Description: Infused on Day 0 - Donor bone marrow or umbilical cord blood will be collected in the usual sterile manner using established parameters determined by the National Marrow Donor Program.
Study NCT03775018 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane blockade
Description: Patients will undergo Transversus abdominis plane blockade with Bupivacaine 0.25% 30ml, applied in the plane between the internal oblique muscle and the trasnversus abdominis. The injection will be performed laterally to the port-sites, bilaterally at the same levels.
Study NCT03775018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous analgesia
Description: Acetaminophen 1g/6h iv will be administered
Study NCT03190772 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Description: The placebo nasal spray consists of sesame oil and does not contain any active drug.
Study NCT03190772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo nasal spray
Description: The placebo nasal spray consists of sesame oil and does not contain any active drug.
Study NCT03190772 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Film sequence
Description: All groups watch the film sequence that is supposed to induce sadness.
Study NCT03190772 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Film sequence
Description: All groups watch the film sequence that is supposed to induce sadness.
Study NCT03190772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Film sequence
Description: All groups watch the film sequence that is supposed to induce sadness.
Study NCT00841152 — intervention group
Intervention type: DEVICE
Intervention: Bioactive glass
Description: Surgical implantation
Study NCT00841152 — intervention group
Intervention type: DEVICE
Intervention: Beta-tricalcium phosphate (ChronOs)
Description: Surgical implantation
Study NCT00841152 — intervention group
Intervention type: PROCEDURE
Intervention: Autograft
Description: Surgical transplantation from iliac crest
Study NCT00841152 — intervention group
Intervention type: PROCEDURE
Intervention: Allograft (frozen femoral head)
Description: Surgical transplantation
Study NCT02270424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol / fluticasone (Seretide®)
Description: According to the revised 2013 GOLD, Salmeterol / fluticasone was used to severe and very severe COPD patients for 52weeks: Salmeterol / fluticasone (Seretide®, GlaxoSmithKline), 50/500 μg / dose, 60 inhalations. 50/500 μg each time, twice daily.
Study NCT02270424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bufeijianpi granule
Description: According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of deficiency of pulmono-splenic qi will be given Bufeijianpi granule, twice daily for 52 weeks for lower dosage.
Study NCT02270424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bufeiyishen granule
Description: According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Bufeiyishen granule, twice daily for 52 weeks for lower dosage.
Study NCT02270424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yiqizishen granule
Description: According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi and yin of the lung and kidney will be given Yiqizishen granule granule, twice daily for 52 weeks for lower dosage.
Study NCT02270424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Bufeijianpi granule
Description: According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of deficiency of pulmono-splenic qi will be given placebo Bufeijianpi granule, twice daily for 52 weeks for lower dosage.
Study NCT00833690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inosine
Description: 500 mg of active substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing titrated to a mildly elevated serum urate range of 6.1 - 7.0 mg/dL
Study NCT00833690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inosine
Description: 500 mg of active substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing titrated to a moderately elevated serum urate range of 7.1 - 8.0 mg/dL
Study NCT02468583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX006 32 mg
Description: Experimental
Study NCT02468583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TCA IR 40 mg
Description: Comparator
Study NCT03640455 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal
Description: A tDCS (Low Current Transcranial Stimulation) device with two electrodes: active and reference, will be used. The tDCS will be applied next to the cortical representation zone of the primary motor cortex and left pre-motor for 30 minutes; intensity 2 mA, in anodal polarity, according to the patient's randomization arm.
Study NCT03640455 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cathodal
Description: A tDCS (Low Current Transcranial Stimulation) device with two electrodes: active and reference, will be used. The tDCS will be applied next to the cortical representation zone of the primary motor cortex and left pre-motor for 30 minutes; intensity 2 mA, in cathodal polarity, according to the patient's randomization arm.
Study NCT01926002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-Dose MK-8351
Description: Single administration of low-dose MK-8351.
Study NCT01926002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-Dose MK-8351
Description: High-Dose MK-8351 administered as a single inhaled dose.
Study NCT01926002 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to MK-8351
Description: Single-Dose Matching placebo to high-dose or low-dose MK-8351.
Study NCT01250548 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: apremilast
Description: 30 mg BID apremilast taken orally for the first 12 weeks followed by responders randomized to either 30 mg BID apremilast (oral) or 30 mg BID placebo (oral) for 8 weeks
Study NCT01250548 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04095403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tarp Assisted Cooling
Description: Body cooling utilizing a tarp and water
Study NCT04095403 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: passive cooling
Description: Supine rest.
Study NCT04611360 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anodal Transcranial Direct Current Stimulation Group
Description: Experimental group were received anodal transcranial direct current stimulation and conventional training exercises for 3 days a weeks for 6 consecutive weeks on alternate days.~Anodal tDCS were given through:~i. Anodal electrode:It has been placed over primary motor cortex(ipsilesional) ii. Cathodal electrode: It has been above contralateral eye. iii. Intensity: 2mA iv Density: 0.07C/cm2 iv. Duration:20 min vi Rectangular electrodes(25cm2 ) inserted in saline soaked sponge used
Study NCT04611360 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Training Exercises Group
Description: Conventional physical exercises were given for 3 days a week on alternate days upto 6 weeks. It includes: progressive Conventional Training Exercises : From Bridging,Sitting: weight-bearing, Standing: weight-bearing, Sit to stand, Squat exercises and Tandem walk.
Study NCT04075357 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amniotic membrane transplantation
Description: Amniotic membrane was located over median nerve during surgery of CTS, prior of closing.
Study NCT01204528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zemplar
Description: Vitamin D receptor activator (VDRA)
Study NCT01204528 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zemplar
Description: Vitamin D receptor activator (VDRA)
Study NCT03353467 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic surgery
Description: Endoscopic nasopharyngectomy included endoscopic resection, with or without posterior pedicle nasal mucoperiosteal flap resurfacing the nasopharyngeal defects.
Study NCT03353467 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-modulated radiotherapy
Description: All of the patients were received irradiation by IMRT. The target volumes were delineated according to a previously described institutional treatment protocol, which is in accordance with the International Commission on Radiation Units and Measurements reports 50 and 62.
Study NCT02764307 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Constant jet nebulizer
Description: A constant jet nebulizer (Neb-easy, Galemed Corp., Taiwan) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.
Study NCT02764307 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breath enhanced nebulizer
Description: A breath enhanced nebulizer (Pari LC plus, Pari Inc., Germany) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.
Study NCT02764307 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual-actuated nebulizer
Description: A manual-actuated nebulizer (A-T Neb, Atlantean Corporation, Taiwan) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.
Study NCT02764307 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breath-actuated nebulizer
Description: A breath-actuated nebulizer (AeroElipes, Trudell Medical Inc, Canada) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.
Study NCT02313090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Welltang
Description: The intervention group installed Welltang (downloaded from www.welltang.com for free) designed by Shanghai Geping Information and Technique Company Ltd (Shanghai, China) on their cell phones. Welltang is a cell phone- based diabetes management application that consists of three main parts: knowledge, self-management, communication between patients and clinicians
Study NCT02167646 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Flap including bilateral nerve branches
Description: Two nerve branches are attached with the flap for sensory coverage
Study NCT02540551 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of radioactive tracer combined with Patent Blue
Description: Blue dye and the radioactive isotope will be injected in the remains of the ligamentum ovarium proprium (median side) and the ligamentum infundibulo-pelvicum (lateral side), just below the peritoneum. Four syringes containing 0,2 ml patent blue and 0,15 ml (20-MBq) radioactive isotope (99mTc-nanocolloid or Nanocoll®, GE Healthcare, Eindhoven, The Netherlands) will be given. After a 15-minute interval the radioactivity the SN(s) will be identified either by the mobile gamma-camera and /or gamma-probe and / or visually (blue dye) after opening the retroperitoneal space.
Study NCT03563391 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New Infant Formula
Description: New Infant Formula is a specialized, nutritionally complete, nutrient-dense infant formula specifically formulated for infants with growth failure.
Study NCT02294929 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Atrial fibrillation ablation
Description: Atrial fibrillation ablation using the Arctic Front™ Advance Cardiac CryoAblation Catheter in two balloon sizes (23mm and 28mm) for pulmonary vein isolation
Study NCT03723512 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non contrast-enhanced magnetic resonance imaging
Description: Non contrast-enhanced magnetic resonance imaging
Study NCT04138771 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: An artificial intelligence system for postoperative management of cataract patients
Description: This system can detect multiple postoperative complications of cataract patients and then provide a management strategy.
Study NCT01568749 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Paracetamol
Study NCT01568749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol formulation 1
Description: Paracetamol
Study NCT02270424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Bufeiyishen granule
Description: According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given placebo Bufeiyishen granule, twice daily for 52 weeks for lower dosage.
Study NCT02270424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Yiqizishen granule
Description: According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi and yin of the lung and kidney will be given placebo Yiqizishen granule granule, twice daily for 52 weeks for lower dosage.
Study NCT02123420 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nobel Replace Tapered Groovy implant; (Nobel Biocare®, Sweden)
Description: Both sites received tapered implants with an anodised surface, one site received: Nobel Replace Tapered Groovy PS implant; (Nobel Biocare, Goteborg, Sweden), with diameters of 4.3 or 5.0 mm and lengths of 10 or 8 mm, (PS group), the contralateral site received Nobel Replace Tapered Groovy implant with Replace Select connection with diameters of 4.3 or 5.0 mm and lengths of 10 or 8 mm, (RP group).~Healing abutments were connected to implants at the same time of surgery , then flaps were sutured with Vicryl 4.0 sutures (Vicryl, Ethicon J\&J International, St-Stevens-Woluwe, Belgium).
Study NCT03775018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous analgesia
Description: Acetaminophen 1g/6h iv will be administered
Study NCT01868178 — intervention group
Intervention type: DEVICE
Intervention: BIS and Spectral Entropy
Description: The aim of the study was investigated the effectiveness of Spectral Entropy and BIS in avoiding awareness
Study NCT01683071 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline 20 mL as single-injection femoral nerve block prior to total knee arthroplasty
Study NCT01683071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXPAREL 67 mg
Description: 5 mL EXPAREL expanded with 15 mL normal saline as single-injection femoral nerve block prior to total knee arthroplasty
Study NCT01683071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXPAREL 133 mg
Description: 10 mL EXPAREL expanded with 10 mL normal saline as single-injection femoral nerve block prior to total knee arthroplasty
Study NCT01683071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXPAREL 266 mg
Description: 20 mL EXPAREL as single-injection femoral nerve block prior to total knee arthroplasty
Study NCT01187108 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: NAC 600 mg oral once daily
Study NCT01187108 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: Acetazolamide 250 mg oral once daily
Study NCT01187108 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo pills
Description: 1 (or 2 in the placebo group) empty gel capsules
Study NCT01187108 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pills
Description: 1 (or 2 in the placebo group) empty gel capsules
Study NCT02114567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP titration
Description: In both groups, PEEP was titrated and set to 0, 40%PEEPi, 80%PEEPi, and 120%PEEPi
Study NCT00436969 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthovisc
Description: Orthovisc injection
Study NCT00436969 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Celestone (betamethasone sodium phosphate and acetate) - 2 mL
Study NCT02608437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGI-110
Description: SGI-110: start at 30 mg/m2 s.c. on W0, 3, 6, 9 Day 1 - 5 q21 days. Dose level -1: 15 mg/m2; dose level +1: 45 mg/m2
Study NCT02608437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: ipilimumab: 3 mg/Kg i.v. over 90 minutes on W1, 4, 7 and 10 for a total of 4 cycles.
Study NCT00926796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Four 500 mg tablets will be administered orally to equal a 2 gm dose.
Study NCT00926796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin
Description: Fixed dose of 240 mg intramuscular one time for patients >45 kg and a 5 mg/kg dose for patients less than or equal to 45 kg based on their measured weight in clinic. Most patients will require 2 injections of gentamicin in separate large muscle groups.
Study NCT00926796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemifloxacin
Description: One 320 mg tablet administered orally.
Study NCT03072121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shexiang Baoxin pill
Description: Conventional western medicine \& shexiang baoxin pill
Study NCT03072121 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SBP placebo
Description: Conventional western medicine \& placebo (for shexiang baoxin pill)
Study NCT03072121 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin Enteric-coated Tablets
Description: 100mg tablet, one tablet daily.
Study NCT03072121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin Enteric-coated Tablets
Description: 100mg tablet, one tablet daily.
Study NCT03072121 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet
Description: one tablet daily. (for patients who can't use aspirin)
Study NCT03072121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet
Description: one tablet daily. (for patients who can't use aspirin)
Study NCT03072121 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin Calcium
Description: 10 mg tablet, two tablets each night.
Study NCT01796964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESBA1008 solution
Description: For intravitreal (IVT) injection
Study NCT01796964 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: For intravitreal (IVT) injection